866-997-4948(US-Canada Toll Free)

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 621 Pages

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes) Pipeline Review, H2 2016, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape.

Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the bodys immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes (Juvenile Diabetes) Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 8, 29, 21, 3, 106, 31 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 29 and 6 molecules, respectively.Type 1 Diabetes (Juvenile Diabetes).

Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 8
Type 1 Diabetes (Juvenile Diabetes) Overview 9
Therapeutics Development 10
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics under Development by Companies 12
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics under Investigation by Universities/Institutes 22
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Products Glance 24
Type 1 Diabetes (Juvenile Diabetes) - Products under Development by Companies 28
Type 1 Diabetes (Juvenile Diabetes) - Products under Investigation by Universities/Institutes 41
Type 1 Diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development 44
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Assessment 150
Drug Profiles 176
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects 566
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products 579
Type 1 Diabetes (Juvenile Diabetes) - Product Development Milestones 582
Appendix 595

List of Tables
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2016 35
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes) - Comparative Analysis, H2 2016 36
Number of Products under Development by Companies, H2 2016 38
Number of Products under Development by Companies, H2 2016 (Contd..1) 39
Number of Products under Development by Companies, H2 2016 (Contd..2) 40
Number of Products under Development by Companies, H2 2016 (Contd..3) 41
Number of Products under Development by Companies, H2 2016 (Contd..4) 42
Number of Products under Development by Companies, H2 2016 (Contd..5) 43
Number of Products under Development by Companies, H2 2016 (Contd..6) 44
Number of Products under Development by Companies, H2 2016 (Contd..7) 45
Number of Products under Development by Companies, H2 2016 (Contd..8) 46
Number of Products under Investigation by Universities/Institutes, H2 2016 47
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 48
Comparative Analysis by Late Stage Development, H2 2016 49
Comparative Analysis by Clinical Stage Development, H2 2016 50
Comparative Analysis by Early Stage Development, H2 2016 51
Comparative Analysis by Unknown Stage Development, H2 2016 52
Products under Development by Companies, H2 2016 53
Products under Development by Companies, H2 2016 (Contd..1) 54
Products under Development by Companies, H2 2016 (Contd..2) 55
Products under Development by Companies, H2 2016 (Contd..3) 56
Products under Development by Companies, H2 2016 (Contd..4) 57
Products under Development by Companies, H2 2016 (Contd..5) 58
Products under Development by Companies, H2 2016 (Contd..6) 59
Products under Development by Companies, H2 2016 (Contd..7) 60
Products under Development by Companies, H2 2016 (Contd..8) 61
Products under Development by Companies, H2 2016 (Contd..9) 62
Products under Development by Companies, H2 2016 (Contd..10) 63
Products under Development by Companies, H2 2016 (Contd..11) 64
Products under Development by Companies, H2 2016 (Contd..12) 65
Products under Investigation by Universities/Institutes, H2 2016 66
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 67
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 68
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AbGenomics International, Inc., H2 2016 69
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Adocia, H2 2016 70
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AiCuris GmbH and Co KG, H2 2016 71
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Alteogen Inc., H2 2016 72
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 73
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ambrx, Inc., H2 2016 74
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AntriaBio, Inc., H2 2016 75
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Aphios Corporation, H2 2016 76
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by APT Therapeutics, Inc., H2 2016 77
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Araim Pharmaceuticals, Inc., H2 2016 78
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Argos Therapeutics, Inc., H2 2016 79
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Artery Therapeutics, Inc., H2 2016 80
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Astellas Pharma Inc., H2 2016 81
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AstraZeneca Plc, H2 2016 82
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Athersys, Inc., H2 2016 83
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Atlantic Bio Sci LLC, H2 2016 84
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Axxam SpA, H2 2016 85
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Beta-Cell NV, H2 2016 86
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biocon Limited, H2 2016 87
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biogenomics Limited, H2 2016 88
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioLineRx, Ltd., H2 2016 89
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioLingus AG, H2 2016 90
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioTherapeutics Inc., H2 2016 91
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BirchBioMed Inc, H2 2016 92
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 93
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Caladrius Biosciences Inc, H2 2016 94
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Cancer Prevention Pharmaceuticals, Inc., H2 2016 95
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Carlina Technologies SAS, H2 2016 96
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Compugen Ltd., H2 2016 97
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ConjuChem, LLC, H2 2016 98
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 99
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Dance Biopharm Inc., H2 2016 100
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diabetology (Products) Ltd, H2 2016 101
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by DiaMedica Inc., H2 2016 102
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diamyd Medical AB, H2 2016 103
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diasome Pharmaceuticals, Inc., H2 2016 104
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 105
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Eli Lilly and Company, H2 2016 106
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by enGene, Inc, H2 2016 107
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ensol Biosciences Inc., H2 2016 108
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by EpiVax, Inc., H2 2016 109
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Escape Therapeutics, Inc., H2 2016 110
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Evotec AG, H2 2016 111
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 112
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Fate Therapeutics, Inc., H2 2016 113
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Generex Biotechnology Corporation, H2 2016 114
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by GeNeuro SA, H2 2016 115
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Geropharm, H2 2016 116
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Gilead Sciences, Inc., H2 2016 117
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by GlaxoSmithKline Plc, H2 2016 118
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Grifols, S.A., H2 2016 119
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Heptares Therapeutics Limited, H2 2016 120
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Iltoo Pharma, H2 2016 121
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ImmusanT, Inc., H2 2016 122
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Innopharmax Inc., H2 2016 123
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Intrexon Corporation, H2 2016 124
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Islet Sciences, Inc., H2 2016 125
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Johnson & Johnson, H2 2016 126
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kadimastem Ltd., H2 2016 127
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kamada Ltd., H2 2016 128
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kasiak Research Private Limited, H2 2016 129
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by KPI Therapeutics, Inc., H2 2016 130
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016 131
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 132
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Lonestar Heart, Inc., H2 2016 133
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MacroGenics, Inc., H2 2016 134
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medestea Research & Production S.p.A., H2 2016 135
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MedImmune LLC, H2 2016 136
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medy-Tox Inc., H2 2016 137
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Merck & Co., Inc., H2 2016 138
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Meridigen Biotech Co., Ltd., H2 2016 139
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MidaSol Therapeutics LP, H2 2016 140
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 141
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Novo Nordisk A/S, H2 2016 142
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Noxxon Pharma AG, H2 2016 143
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Oramed Pharmaceuticals, Inc., H2 2016 144
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Orgenesis Inc, H2 2016 145
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by OSE Immunotherapeutics, H2 2016 146
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016 147
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Parvus Therapeutics, Inc., H2 2016 148
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Pathfinder Cell Therapy Inc, H2 2016 149
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Pfizer Inc., H2 2016 150
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by PharmaCyte Biotech, Inc., H2 2016 151
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by PharmaIN Corporation, H2 2016 152
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Prometheon Pharma, LLC, H2 2016 153
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Purzer Pharmaceutical Co., Ltd., H2 2016 154
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by RedHill Biopharma Ltd., H2 2016 155
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by REGiMMUNE Corporation, H2 2016 156
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Sanofi, H2 2016 157
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by SEKRIS Biomedical, Inc., H2 2016 158
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Selecta Biosciences, Inc., H2 2016 159
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Semma Therapeutics Inc., H2 2016 160
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Sevion Therapeutics, Inc., H2 2016 161
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Strongbridge Biopharma plc , H2 2016 162
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Therapix Biosciences Ltd., H2 2016 163
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Thermalin Diabetes, LLC, H2 2016 164
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Toleranzia AB, H2 2016 165
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Transgene Biotek Limited, H2 2016 166
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by UCB SA, H2 2016 167
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Unicyte AG, H2 2016 168
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by United Therapeutics Corporation, H2 2016 169
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ViaCyte, Inc., H2 2016 170
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Visionary Pharmaceuticals, Inc., H2 2016 171
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XL-protein GmbH, H2 2016 172
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XOMA Corporation, H2 2016 173
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2016 174
Assessment by Monotherapy Products, H2 2016 175
Assessment by Combination Products, H2 2016 176
Number of Products by Stage and Target, H2 2016 178
Number of Products by Stage and Mechanism of Action, H2 2016 188
Number of Products by Stage and Route of Administration, H2 2016 198
Number of Products by Stage and Molecule Type, H2 2016 200
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H2 2016 591
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..1), H2 2016 592
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..2), H2 2016 593
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..3), H2 2016 594
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..4), H2 2016 595
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..5), H2 2016 596
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..6), H2 2016 597
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..7), H2 2016 598
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..8), H2 2016 599
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..9), H2 2016 600
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..10), H2 2016 601
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..11), H2 2016 602
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..12), H2 2016 603
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, H2 2016 604
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products (Contd..1), H2 2016 605
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products (Contd..2), H2 2016 606

List of Figures
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2016 35
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes) - Comparative Analysis, H2 2016 36
Number of Products under Development by Companies, H2 2016 37
Number of Products under Investigation by Universities/Institutes, H2 2016 47
Comparative Analysis by Late Stage Development, H2 2016 49
Comparative Analysis by Clinical Stage Development, H2 2016 50
Comparative Analysis by Early Stage Products, H2 2016 51
Assessment by Monotherapy Products, H2 2016 175
Assessment by Combination Products, H2 2016 176
Number of Products by Top 10 Targets, H2 2016 177
Number of Products by Stage and Top 10 Targets, H2 2016 177
Number of Products by Top 10 Mechanism of Actions, H2 2016 187
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 187
Number of Products by Top 10 Routes of Administration, H2 2016 197
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 197
Number of Products by Top 10 Molecule Types, H2 2016 199
Number of Products by Stage and Top 10 Molecule Types, H2 2016 199

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *